Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

NCT05446467 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

COMBINATION_PRODUCT: pembrolizumab+cisplatin + 5-FU

Sponsor

Zhejiang Provincial People's Hospital